Empowering your research with mRNA technology

learn more
Application
At the inception of mRNA therapeutic design, we must first define our objective—the disease to be treated or the health condition to be improved. Through rigorous research and data analysis, we identify the protein that needs to be encoded.
Protein
Subsequently, we select the target protein.
This involves recognizing proteins associated
with the disease and understanding
their structure and function.
MFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRRARSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT
Protein Sequence Optimization
We then optimize the selected protein sequence to ensure its stability and functionality within the human body. Using computational simulations and bioinformatics tools, we can predict and improve the protein's structure for enhanced efficacy.
AUGUUCGUGUUUUUGGUUCUGCUACCACUUGUUUCAUCCCAGUGCGUGAACCUUACAACACGGACGCAGUUGCCGCCUGCGUACACUAAUUCAUUCACGCGAGGGGUGUAUUACCCGGACAAGGUGUUUCGUUCGUCGGUGCUUCACUCCACGCAAGACCUAUUCCUGCCAUUUUUCUCUAAUGUCACGUGGUUUCACGCGAUUCAUGUGAGUGGCACGAAUGGCACUAAACGUUUCGACAACCCGGUAUUACCGUUUAAUGACGGGGUGUACUUCGCCUCGACAGAGAAAUCAAAUAUCAUUAGAGGCUGGAUCUUUGGCACAACACUAGACUCUAAGACGCAAAGCUUGCUUAUUGUAAAUAAUGCUACCAAUGUCGUUAUCAAAGUAUGUGAAUUUCAAUUCUGCAAUGACCCGUUCCUUGGGGUAUAUUAUCAUAAAAAUAAUAAGUCUUGGAUGGAGAGUGAGUUUAGAGUCUAUUCGUCGGCAAACAAUUGUACUUUUGAGUACGUUUCACAACCUUUCUUAAUGGAUCUGGAGGGCAAACAAGGGAAUUUCAAGAACUUGAGGGAGUUUGUGUUCAAGAAUAUUGAUGGCUACUUCAAAAUUUACAGUAAACACACACCGAUUAAUUUAGUACGUGAUCUACCCCAGGGGUUUUCCGCCCUCGAGCCACUCGUGGACCUUCCUAUUGGAAUCAAUAUAACCCGGUUCCAGACAUUGUUAGCCCUUCAUAGGAGCUAUUUAACUCCAGGAGACAGCUCUUCGGGCUGGACAGCGGGAGCGGCAGCGUAUUACGUCGGCUAUUUGCAGCCCCGUACCUUUCUAUUAAAGUACAAUGAGAAUGGCACUAUUACGGAUGCGGUUGAUUGCGCUCUGGACCCCUUGUCCGAAACAAAGUGUACCCUCAAGUCGUUCACUGUCGAAAAGGGCAUCUAUCAGACGAGUAAUUUCCGUGUACAACCGACGGAGUCGAUAGUUCGCUUUCCAAAUAUUACCAAUCUUUGUCCAUUCGGCGAGGUCUUUAACGCAACUCGAUUCGCUUCCGUUUACGCCUGGAACCGGAAACGGAUAAGCAACUGUGUGGCGGACUAUAGCGUCCUGUACAAUUCUGCGAGCUUCUCAACAUUUAAGUGUUAUGGAGUGAGCCCCACUAAAUUGAAUGACCUCUGCUUCACCAAUGUCUAUGCGGACUCCUUUGUAAUCCGGGGUGAUGAGGUACGACAAAUUGCACCCGGCCAGACGGGGAAAAUCGCUGAUUACAAUUAUAAGCUACCGGACGACUUUACCGGCUGCGUAAUAGCGUGGAACUCUAACAACCUCGAUUCUAAGGUGGGUGGGAACUACAACUAUCUGUACAGGCUAUUUCGAAAAUCUAAUCUUAAGCCUUUUGAACGCGAUAUUUCAACUGAAAUUUAUCAGGCCGGGUCAACGCCUUGCAACGGGGUGGAGGGGUUUAAUUGCUAUUUCCCGUUGCAAUCCUACGGCUUUCAGCCGACAAACGGAGUAGGAUACCAACCGUACCGAGUAGUAGUAUUAUCCUUCGAACUUUUACACGCACCGGCGACCGUUUGCGGUCCAAAGAAGUCUACUAAUCUAGUAAAAAACAAAUGUGUUAAUUUCAACUUUAACGGGUUGACUGGCACAGGCGUUCUGACUGAGUCUAACAAAAAGUUCCUGCCGUUUCAACAAUUUGGUAGAGAUAUAGCGGACACCACUGAUGCAGUAAGAGAUCCCCAAACGCUGGAAAUUCUAGACAUCACACCCUGUUCCUUUGGAGGUGUCUCUGUGAUCACUCCCGGGACUAAUACCAGCAAUCAAGUCGCGGUUCUCUACCAGGAUGUCAACUGUACAGAGGUACCGGUAGCAAUCCAUGCUGAUCAGCUAACGCCGACUUGGAGAGUCUACAGCACCGGAUCUAACGUUUUUCAGACGCGGGCUGGGUGUCUAAUAGGCGCGGAGCACGUAAACAAUUCAUAUGAGUGUGAUAUACCCAUCGGUGCCGGGAUCUGCGCUUCAUACCAGACACAAACUAAUAGCCCAAGGCGCGCUCGAUCCGUGGCUAGUCAGAGUAUUAUAGCUUAUACGAUGUCCUUAGGAGCAGAGAAUUCUGUCGCCUAUAGUAACAAUUCAAUUGCUAUCCCUACCAAUUUCACGAUCUCUGUUACUACCGAGAUUUUACCAGUUAGCAUGACCAAAACGAGCGUGGAUUGUACAAUGUAUAUUUGUGGAGACAGCACAGAAUGUUCGAAUCUACUGCUACAGUAUGGCAGUUUUUGCACACAAUUAAAUAGAGCGCUGACAGGCAUUGCCGUGGAACAGGAUAAAAAUACCCAGGAAGUCUUCGCACAAGUAAAGCAAAUUUACAAAACCCCGCCGAUCAAAGAUUUUGGCGGGUUUAAUUUCUCACAGAUACUGCCCGAUCCUAGUAAGCCCAGCAAACGUAGUUUCAUAGAAGACUUGCUCUUCAACAAAGUAACGUUGGCAGAUGCAGGAUUUAUUAAACAAUAUGGUGACUGUCUAGGGGACAUUGCAGCGCGCGAUUUAAUUUGUGCGCAAAAAUUCAACGGACUCACGGUGCUGCCGCCCUUAUUGACGGACGAGAUGAUAGCGCAAUAUACGUCAGCACUCUUGGCGGGGACCAUAACCUCGGGCUGGACCUUCGGCGCCGGAGCCGCGUUGCAGAUACCAUUUGCUAUGCAAAUGGCGUAUAGAUUCAACGGAAUCGGGGUAACUCAAAACGUUCUUUAUGAAAACCAGAAACUGAUCGCCAACCAGUUCAAUAGCGCCAUUGGCAAAAUACAAGACAGCUUGUCAUCAACAGCCUCUGCACUGGGUAAAUUACAGGAUGUUGUAAACCAGAAUGCGCAAGCUUUAAACACUCUUGUGAAACAACUCUCGUCAAAUUUCGGGGCUAUCAGCUCUGUGCUCAAUGACAUACUCUCGAGACUUGAUAAGGUGGAGGCAGAAGUACAAAUUGAUAGGCUGAUUACUGGUCGUCUCCAAUCCCUUCAAACUUAUGUUACUCAGCAACUGAUCAGAGCAGCUGAGAUUCGUGCAUCGGCGAACCUGGCAGCUACUAAGAUGUCAGAGUGCGUCUUAGGCCAGUCAAAGCGGGUGGACUUCUGUGGGAAAGGCUACCACCUCAUGUCAUUCCCCCAGUCAGCUCCACAUGGCGUGGUUUUCUUACAUGUGACGUACGUUCCAGCGCAGGAGAAAAAUUUCACAACAGCUCCAGCCAUAUGUCAUGAUGGUAAGGCGCACUUCCCUCGGGAAGGCGUCUUUGUCUCUAACGGCACUCAUUGGUUUGUGACCCAGCGCAAUUUUUAUGAACCUCAAAUAAUAACAACGGAUAACACGUUCGUGAGCGGAAAUUGUGAUGUGGUGAUCGGCAUAGUGAACAACACAGUAUACGACCCUCUCCAACCGGAACUCGAUUCCUUCAAAGAAGAACUUGACAAAUACUUUAAAAACCAUACCUCCCCAGAUGUAGACCUUGGUGACAUAUCUGGUAUUAAUGCAUCCGUGGUUAACAUACAGAAAGAAAUAGAUCGACUUAACGAGGUGGCUAAGAACUUAAACGAAUCCCUCAUCGACCUCCAAGAGUUAGGAAAGUACGAACAGUACAUCAAGUGGCCAUGGUAUAUUUGGUUAGGAUUCAUCGCUGGACUCAUAGCUAUCGUUAUGGUGACAAUAAUGCUGUGCUGCAUGACGUCGUGUUGUUCUUGCUUAAAGGGAUGUUGUUCCUGCGGUUCUUGUUGCAAAUUUGAUGAGGACGACUCAGAGCCCGUGCUUAAGGGCGUUAAGCUGCAUUACACGUAG
mRNA Sequence Optimization
To ensure stability and efficient translation of mRNA within the body, we optimize various components of the mRNA sequence. This includes the 5' Cap, the 5' Untranslated Region (5' UTR), the Coding Sequence (CDS), the 3' Untranslated Region (3' UTR), and the PolyA tail.
mRNA Manufacture
The optimized mRNA sequence is synthesized in the laboratory. This process demands high-precision instruments and stringent quality control measures to ensure the production of mRNA with high purity and activity.
5' Cap
The 5' Cap is the cap-like structure at the beginning of the mRNA molecule, which protects the mRNA from degradation and facilitates the initiation of translation. By optimizing the 5' Cap, we can enhance the stability and translational efficiency of the mRNA, allowing it to remain functional within the cell for a longer period.
5' UTR
The 5' Cap is the cap-like structure at the beginning of the mRNA molecule, which protects the mRNA from degradation and facilitates the initiation of translation. By optimizing the 5' Cap, we can enhance the stability and translational efficiency of the mRNA, allowing it to remain functional within the cell for a longer period.
CDS
The Coding Sequence is the portion of the mRNA that is actually translated into protein. By optimizing codon usage frequency and folding energy, we can improve translational efficiency and stability, resulting in increased protein expression levels.
3' UTR
The 3' Untranslated Region is found between the CDS and the PolyA tail, influencing both mRNA stability and translational efficiency. By optimizing the sequence of the 3' UTR, we can extend the mRNA's half-life and decrease its degradation rate.
PolyA
The PolyA tail is a string of adenosine nucleotides at the end of the mRNA molecule, serving to protect the mRNA and promote translation. An optimized PolyA tail effectively shields the mRNA from degradation by cellular nucleases.
Encapsulation
To protect the mRNA and facilitate its entry into cells, we encapsulate it in lipid nanoparticles (LNPs). These nanoparticles effectively evade detection by the immune system and safely deliver the mRNA to target cells.
mRNA Released
Once inside the cell, the encapsulated mRNA is released into the cytoplasm. Here, the cellular translational machinery commences, converting the mRNA into the target protein. This step is critical for the therapeutic action of mRNA drugs.
Protein Functions
Ultimately, the translated protein begins exerting its biological functions within the cell. Whether repairing damaged cells, modulating immune responses, or inhibiting pathogen proliferation, these proteins work towards achieving therapeutic effects and enhancing patient health.